Company: ABUS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001447028-25-000083
Chunk: 27

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 16
Chunk 27
---
Item 16.             Form 10-K Summary

    None.

 109

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 27, 2025.

 ARBUTUS BIOPHARMA CORPORATION    By:/s/ Lindsay Androski  Lindsay Androski  President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on March 27, 2025.

SignaturesCapacity in Which Signed  /s/ Lindsay AndroskiPresident, Chief Executive Officer and Director (Chairperson)Lindsay Androski(Principal Executive Officer)/s/ David C. HastingsChief Financial OfficerDavid C. Hastings(Principal Financial Officer and Principal Accounting Officer)  /s/ Robert Alan BeardsleyDirectorRobert Alan Beardsley  /s/ Joseph BishopDirectorJoseph Bishop   /s/ Matthew GlineDirectorMatthew Gline /s/ Anuj HasijaDirectorAnuj Hasija 

 110